North America Chronic Idiopathic Constipation Drug Market Forecast 2017-2025

Publisher Name :
Date: 24-Sep-2017
No. of pages: 68

Key Findings

The North America Chronic Idiopathic Constipation Drug Market is expected to grow at a CAGR of 6.92%. The market value is expected to rise from $1822 million in 2016 to $3358 million by 2025. The changing modern dietary habits, chances of cancer or other systematic disease leading to CIC and the growing increasing elderly population are some of the factors driving the market.

Market Insights

The North America chronic idiopathic constipation drug market is segmented on the basis of drug types and on the basis of the type of prescriptions. The drug type can be further divided into lubiprostone and linaclotide, with the former being a more popular drug. The prescription drug market can be further segmented into over the counter drugs and prescribed drugs. Continuous government initiatives and the already flourishing healthcare and medical industry in countries such as the United States and Canada are benefiting the CIC market growth in this region.

Competitive Insights

Some of the major players in the market include Chugai Pharmaceutical, Allergens, Synergy Pharmaceuticals, Ferring International Center S.A., Pfizer, GlaxoSmithKline, Roche Holding Ag, Merck Sharp & Dohme, Sanofi, Bayer Ag, Eli Lilly And Company, Sucampo Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, Theravance Biopharma Inc and Progenics Pharmaceuticals Inc.

North America Chronic Idiopathic Constipation Drug Market Forecast 2017-2025

Table of Contents

1. Research Scope
1.1. Study Goals
1.2. Scope of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study and Forecasting Years
2. Research Methodology
2.1. Sources of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-Up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
4. Market Overview
4.1. Market Definition
4.2. Key Market Insights
4.3. Attractive Investment Scenario
4.4. Positioning of Key Cic Drugs Manufacturers In The Market
4.5. Market Drivers
4.5.1. Modern Dietary Habits Taking Toll On The Health
4.5.2. Cancer Or Other Systematic Disease Can Lead To Cic
4.5.3. Increasing Elderly Population
4.5.4. Improved and Efficient Drugs In Pipeline
4.5.5. Increasing Constipation Problems Due To Side Effects of Prescribed Medicines
4.6. Restraints
4.6.1. Surgical Treatments
4.6.2. Unawareness and Ignorance Among People
4.7. Opportunities
4.7.1. High Unmet Needs
4.8. Challenges
4.8.1. Side Effects of Cic Drugs
5. North America Cic Drugs Market, By Drug Type 2017-2025 ($ Million)
5.1. Overview
5.1.1. Lubiprostone
5.1.2. Linaclotide
5.1.3. Others
5.2. Pipeline Drug Analysis: Phase 3: Plecanatide (Year of Launch 2022, $ Million)
5.3. Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch 2022, $ Million)
6. North America Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
6.1. Prescribed Drugs
6.2. Over The Counter Drugs
7. Key Analytics
7.1. Porters Five Force Analysis
7.1.1. Intensity of Competitive Rivalry
7.1.2. Bargaining Power of Suppliers
7.1.3. Bargaining Power of Buyers
7.1.4. Threat of Substitute Products
7.1.5. Threat of New Entrants
7.2. Vendor Landscape
7.3. Opportunity Matrix
8. North America Cic Drugs Market By Countries 2017-2025 ($ Million)
8.1. Us
8.2. Canada
9. Company Profiles
9.1. Allergens
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Strategic Moves
9.1.4. Scot Analysis
9.2. Chugai Pharmaceutical
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Strategic Moves
9.2.4. Scot Analysis
9.3. Ferring International Center S.A.
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Scot Analysis
9.4. Synergy Pharmaceuticals
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Scot Analysis
9.5. Pfizer
9.5.1. Overview
9.5.2. Pfizer Product Portfolio
9.5.3. Scot Analysis
9.6. Glaxosmithkline
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Scot Analysis
9.7. Roche Holding Ag
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Strategic Moves
9.7.4. Scot Analysis
9.8. Sanofi
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Scot Analysis
9.9. Bayer Ag
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.10. Merck Sharp & Dohme
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Scot Analysis
9.11. Eli Lilly and Company
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Scot Analysis
9.12. Salix Pharmaceuticals Ltd
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Scot Analysis
9.13. Sucampo Pharmaceuticals Inc
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Scot Analysis
9.14. Ironwood Pharmaceuticals Inc
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Scot Analysis
9.15. Valeant Pharmaceuticals International
9.15.1. Overview
9.16. Daiichi Sankyo Co Ltd
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Scot Analysis
9.17. Cosmo Pharmaceuticals Sa
9.17.1. Overview
9.17.2. Product Portfolio
9.17.3. Scot Analysis
9.18. Progenics Pharmaceuticals Inc
9.18.1. Overview
9.18.2. Product Portfolio
9.18.3. Scot Analysis
9.19. Theravance Biopharma Inc
9.19.1. Overview
9.19.2. Product Portfolio
9.19.3. Scot Analysis
List of Tables
Table 1 North America Cic Drug Market By Countries 2017-2025 ($ Million)
Table 2 Prominent Drugs and Their Respective Companies In Therapeutics For Chronic Constipation
Table 3 Constipation In Parkinson's Disease
Table 4 Common Medicines Causing Constipation
Table 5 North America Cic Drugs Market By Drug Type 2014-2022($ Million)
Table 6 Product Profile (Lubiprostone)
Table 7 Product Profile (Linaclotide)
Table 8 Product Profile (Bisacodyl)
Table 9 Pipeline Product Profile (Plecanatide)
Table 10 Pipeline Product Profile (Elobixibat)
Table 11 North America Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
Table 12 Linzess Precautions and Side Effects
Table 13 North America Cic Drugs Market By Country 2017-2025 ($ Million)
Table 14 U.S. Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
Table 15 U.S. Cic Drugs Market By Major Drugs 2017-2025 ($ Million)
Table 16 Canada Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
Table 17 Canada Cic Drugs Market By Major Drugs 2017-2025 ($ Million)

List of Figures
Figure 1 North America Chronic Idiopathic Constipation (Cic) Drug Market 2017-2025 ($ Million)
Figure 2 North America Cic Drug Market By Drug Type 2017-2025 ($ Million)
Figure 3 North America Cic Drug Market By Prescription Type In 2016 ($ Million)
Figure 4 Causes of Constipation
Figure 5 Proportion of Population Aged 60 Or Above In 2014
Figure 6 Major Causes of Constipation In Elderly People
Figure 7 Effective Drugs To Create Huge Market Benefits
Figure 8 Surgical Options Available For Constipation
Figure 9 Need of Surgery Process
Figure 10 Common Constipation Drugs and Side Effects Caused Due To Them
Figure 11 North America Lubiprostone Drug Market 2017-2025 ($ Million)
Figure 12 North America Linaclotide Drug Market 2017-2025 ($ Million)
Figure 13 North America Other Drugs Market 2017-2025 ($ Million)
Figure 14 North America Prescribed Cic Drugs Market 2017-2025 ($ Million)
Figure 15 North America Over The Counter Cic Drug Market 2017-2025 ($ Million)
Figure 16 North America Cic Drugs Market 2017-2025 ($ Million)
Figure 17 Us Cic Market, 2017-2025 ($ Million)
Figure 18 Canada Cic Market 2017-2025 ($ Million)
  • Global Gastrointestinal OTC Drugs Market Research Report 2017
    Published: 13-Nov-2017        Price: US 2900 Onwards        Pages: 114
    In this report, the global Gastrointestinal OTC Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Gastrointestinal OTC Drugs in these regions, from 2012 to 2022 (forecast), covering - North America - Europe......
  • Gastritis - Pipeline Review, H2 2017
    Published: 07-Nov-2017        Price: US 2000 Onwards        Pages: 51
    Gastritis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Pipeline Review, H2 2017, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape. Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gast......
  • Irritable Bowel Syndrome - Pipeline Review, H2 2017
    Published: 07-Nov-2017        Price: US 2000 Onwards        Pages: 154
    Irritable Bowel Syndrome - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2017, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape. Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Si......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Gastrointestinal Drug Market 2017 Forecast to 2022
    Published: 06-Nov-2017        Price: US 4880 Onwards        Pages: 121
    Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. Scope of the Report: This report focuses on the Gastrointestinal Drug in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes......
  • Short Bowel Syndrome - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Short Bowel Syndrome - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Short Bowel Syndrome for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Short Bowel Syndrome . It enables understand......
  • Irritable Bowel Syndrome (IBS) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Irritable Bowel Syndrome (IBS) - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Irritable Bowel Syndrome (IBS) - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients af......
  • Gastric Ulcers - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Gastric Ulcers - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Gastric Ulcers. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Gastric Ulcers which can turn out t......
  • Helicobacter Pylori Infections - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 1500 Onwards        Pages: 40
    DelveInsight's, Helicobacter Pylori Infections - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Helicobacter Pylori Infections. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Hel......
  • Traveler's Diarrhea - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Traveler's Diarrhea - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Traveler's Diarrhea for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Traveler's Diarrhea . It enables understanding......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs